Advertisement

Experience of using ISGTL-2 in patients with DM2 and HIV infection

Published:March 18, 2017DOI:https://doi.org/10.1016/j.ejim.2017.03.002
      It is estimated that up to 14% of patients with HIV have diabetes mellitus (DM), which is a determinant risk factor for the development of cardiovascular disease [
      • Paik I.J.
      • Kotler D.P.
      The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.
      ]. The therapeutic regimen is the same as that recommended in clinical practice guidelines such as the American Diabetes Association (ADA) and the European Diabetes Association (EASD) [
      • American Diabetes Association
      Standards of medical care in diabetes—2016.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Paik I.J.
        • Kotler D.P.
        The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.
        Best Pract Res Clin Endocrinol Metab. 2011; 25: 469-478
        • American Diabetes Association
        Standards of medical care in diabetes—2016.
        Diabetes Care. 2016; 39
        • Vasilakou D.
        • Karagiannis T.
        • Athanasiadou E.
        • et al.
        Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
        Ann Intern Med. 2013; 159: 262-274
        • Nauck M.A.
        Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
        Drug Des Devel Ther. 2014; 11: 1335-1380
        • Thayer S.
        • Chow W.
        • Korrer S.
        • Aguilar R.
        Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
        Curr Med Res Opin. 2016; 32: 1087-1096